Menu
← Oncology Approval Tracker
FDA DECISION ·
Anktiva + BCG
nogapendekin alfa inbakicept-pmln with BCG · Altor BioScience
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with BCG-unresponsive non-muscle-invasive bladder cancer and carcinoma in situ, with or without papillary tumors; use with intravesical BCG.
LAMPGEN ANALYSIS
Why it matters
The cytokine-based combination provides a bladder-directed option in the defined BCG-unresponsive setting.
What research teams should watch
Reconstruct BCG treatment adequacy and recurrence timing, and plan repeat cystoscopy and urine cytology.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
BCG-unresponsive non-muscle-invasive bladder cancerPRIMARY RECORDS